CompanyGraph
Zhejiang Cheng Yi Pharmaceutical Co., Ltd.
603811 · SSE · China
chengyipharma.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $34.53M, above the global median of $16.24M
- FinancialsAltman Z-Score 8.57: safe zone
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
4.05%Above 5Y avg (2.22%)
Annual Rate
CNY 0.30Paid annual
Payout Ratio
41.0%Sustainable
Payback Period
24.7 yr
Last Ex-Dividend
Jun 26, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.50BCNY519.93M · vs all stocks (USD)
Trailing P/E
17.48xRevenue (TTM)
827.75MCNY123.10M · vs all stocks (USD)
Profit Margin
23.39%Beta
0.0720xvs all stocks
52-Week Change
-28.21%vs all stocks
Market Capitalization
3.50BCNY519.93M · vs all stocks (USD)
Enterprise Value
3.13BCNY466.07M · vs all stocks (USD)
Trailing P/E
17.48xPrice to Sales (TTM)
4.26xPrice to Book (MRQ)
2.36xEnterprise to Revenue
3.79xEnterprise to EBITDA
11.89xGross Margin
69.96%Profit Margin
23.39%Operating Margin
22.13%Return on Assets (TTM)
6.13%Return on Equity (TTM)
14.13%Revenue (TTM)
827.75MCNY123.10M · vs all stocks (USD)
Revenue per Share (TTM)
1.86CNYUpdated Aug 21, 2026Quarterly Revenue Growth
8.30%Gross Profit (TTM)
570.69MCNY84.87M · vs all stocks (USD)
EBITDA (TTM)
234.20MCNY34.83M · vs all stocks (USD)
Net Income (TTM)
193.61MCNY28.79M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-3.30%Operating Cash Flow (TTM)
279.11MCNY41.51M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
232.23MCNY34.53M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.3000CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
4.05%vs all stocks
5-Year Average Dividend Yield
2.22%vs all stocks
Payout Ratio
40.98%Minority Interest (Equity)
7.33MCNYFY2025 · Dec 31, 2025Revenue
812.35MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
245.34MCNYFY2025 · Dec 31, 2025Gross Profit
567.01MCNYFY2025 · Dec 31, 2025Operating Income
185.55MCNY27.59M · vs all stocks (USD)
Pre-tax Income
223.84MCNYFY2025 · Dec 31, 2025Income Tax Expense
26.38MCNYFY2025 · Dec 31, 2025Net Income
197.47MCNYFY2025 · Dec 31, 2025EBIT
227.67MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
312.41MCNYFY2025 · Dec 31, 2025Research & Development
44.44MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
194.52MCNYFY2025 · Dec 31, 2025Other Operating Expenses
17.55MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
233.97KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
3.83MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.4357CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.4357CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
447.81MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
447.81MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
197.47MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-2.35MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
165.51MCNYFY2025 · Dec 31, 2025Free Cash Flow
159.10MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
217.11MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
197.47MCNYFY2025 · Dec 31, 2025Other Non-cash Items
4.36MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-41.04MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
4.73MCNYFY2025 · Dec 31, 2025Capital Expenditures
-6.42MCNYFY2025 · Dec 31, 2025Sale of Investments
11.25MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
4.83MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
65.70MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-258.56MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-83.48MCNYFY2025 · Dec 31, 2025Other Financing Charges
39.13MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-237.21MCNYFY2025 · Dec 31, 2025Shares Outstanding
458.23MSharesUpdated Aug 21, 2026Float Shares
263.65MSharesUpdated Aug 21, 2026% Held by Insiders
39.49%vs all stocks
% Held by Institutions
1.53%vs all stocks
Total Cash (MRQ)
268.78MCNY39.97M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.6040CNYUpdated Aug 21, 2026Total Debt (MRQ)
55.06MCNY8.19M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0377xCurrent Ratio (MRQ)
1.75xBook Value per Share (MRQ)
3.26CNYUpdated Aug 21, 2026Total Assets
1.70BCNY253.16M · vs all stocks (USD)
Total Current Assets
395.49MCNYFY2025 · Dec 31, 2025Total Liabilities
304.55MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.31BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
38.22MCNYFY2025 · Dec 31, 2025Total Current Liabilities
266.33MCNYFY2025 · Dec 31, 2025Cash
130.34MCNYFY2025 · Dec 31, 2025Cash Equivalents
365.95KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
220.70MCNYFY2025 · Dec 31, 2025Accounts Receivable
22.58MCNYFY2025 · Dec 31, 2025Inventory
116.34MCNYFY2025 · Dec 31, 2025Accounts Payable
53.69MCNYFY2025 · Dec 31, 2025Short-term Debt
32.06MCNYFY2025 · Dec 31, 2025Other Current Liabilities
600.96KCNYFY2025 · Dec 31, 2025Long-term Debt
5.70MCNYFY2025 · Dec 31, 2025Common Stock (Book)
327.30MCNYFY2025 · Dec 31, 2025Retained Earnings
820.04MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.40BCNY207.87M · vs all stocks (USD)
Treasury Stock
48.29MCNYFY2025 · Dec 31, 202552-Week Low
6.83CNYUpdated Aug 21, 202652-Week High
10.97CNYUpdated Aug 21, 202652-Week Change
-28.21%vs all stocks
Beta
0.0720xvs all stocks
50-Day MA
7.45CNYUpdated Aug 21, 2026200-Day MA
7.99CNYUpdated Aug 21, 2026Avg 10-Day Volume
7.15MSharesUpdated Aug 21, 2026Avg 30-Day Volume
6.32MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.4400CNYUpdated Aug 21, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
Debt Falling While Share Count Rises
Debt has fallen for four years while the share count rose over eight.
Reads
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Diagnostic
Rising Operating Income With Low Depreciation on a Capital-Heavy Balance Sheet
Operating income rose four years, with small depreciation on a capital-heavy balance sheet.
Reads
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 8.57: safe zoneNotable
Altman Z-Score: 8.57
High earnings qualityNotable
Earnings Quality Score: 0.62
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $34.53M, above the global median of $16.24MNotable
Levered free cash flow (USD): 34,534,885.23Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
IOL Chemicals and Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aim Vaccine Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zura Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lifecome Biochemistry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aquestive Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Arvinas Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Eiken Chemical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pharmicell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Wuhan Easydiagnosis Biomedicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Bioperfectus Technologies Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Hamilton Lane Inc.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesRising Operating Income With Low Depreciation on a Capital-Heavy Balance SheetCash Backing With Revenue And Income Streaks
Pegasystems Inc.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksDebt Falling While Share Count Rises
Suzhou Sepax Technologies Inc.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksDebt Falling While Share Count Rises